Aggressive blood pressure reduction is not associated with decreased perfusion in leukoaraiosis regions in acute intracerebral hemorrhage patients.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 22 05 2018
accepted: 17 02 2019
entrez: 12 3 2019
pubmed: 12 3 2019
medline: 27 12 2019
Statut: epublish

Résumé

Leukoaraiosis regions may be more vulnerable to decreases in cerebral perfusion. We aimed to assess perfusion in leukoaraiosis regions in acute intracerebral hemorrhage (ICH) patients. We tested the hypothesis that aggressive acute BP reduction in ICH patients is associated with hypoperfusion in areas of leukoaraiosis. In the ICH Acutely Decreasing Arterial Pressure Trial (ICH ADAPT), patients with ICH <24 hours duration were randomized to two systolic BP (SBP) target groups (<150 mmHg vs. <180 mmHg). Computed tomography perfusion (CTP) imaging was performed 2h post-randomization. Leukoaraiosis tissue volumes were planimetrically measured using semi-automated threshold techniques on the acute non-contrast CT. CTP source leukoaraiosis region-of-interest object maps were co-registered with CTP post-processed maps to assess cerebral perfusion in these areas. Seventy-one patients were included with a mean age of 69±11.4 years, 52 of whom had leukoaraiosis. The mean relative Tmax (rTmax) of leukoaraiotic tissue (2.3±2s) was prolonged compared to that of normal appearing white matter in patients without leukoaraiosis (1.1±1.2s, p = 0.04). In the 52 patients with leukoaraiosis, SBP in the aggressive treatment group (145±20.4 mmHg, n = 27) was significantly lower than that in the conservative group (159.9±13.1 mmHg, n = 25, p = 0.001) at the time of CTP. Despite this SBP difference, mean leukoaraiosis rTmax was similar in the two treatment groups (2.6±2.3 vs. 1.8±1.6 seconds, p = 0.3). Cerebral perfusion in tissue affected by leukoaraiosis is hypoperfused in acute ICH patients. Aggressive BP reduction does not appear to acutely aggravate cerebral hypoperfusion.

Identifiants

pubmed: 30856236
doi: 10.1371/journal.pone.0213645
pii: PONE-D-18-15025
pmc: PMC6411275
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0213645

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Cereb Blood Flow Metab. 2014 Feb;34(2):242-7
pubmed: 24192640
Magn Reson Med. 1996 Nov;36(5):726-36
pubmed: 8916023
Neurology. 2002 Aug 13;59(3):321-6
pubmed: 12177363
Clin Radiol. 1999 Jul;54(7):422-9
pubmed: 10437691
Neurology. 1995 Nov;45(11):2077-84
pubmed: 7501162
IEEE Trans Med Imaging. 2001 Sep;20(9):854-67
pubmed: 11585203
Brain. 2011 Aug;134(Pt 8):2376-86
pubmed: 21841203
J Stroke Cerebrovasc Dis. 2013 Oct;22(7):919-25
pubmed: 23433781
Stroke. 2015 May;46(5):1233-8
pubmed: 25804924
Int J Stroke. 2010 Jun;5(3):227-33
pubmed: 20536619
Hypertension. 1994 May;23(5):565-8
pubmed: 8175162
Cerebrovasc Brain Metab Rev. 1990 Summer;2(2):161-92
pubmed: 2201348
Stroke. 2013 Mar;44(3):620-6
pubmed: 23391776
Stroke. 2002 Apr;33(4):972-6
pubmed: 11935046
Stroke. 2010 Oct;41(10 Suppl):S139-43
pubmed: 20876490
Stroke. 2015 Jun;46(6):1541-7
pubmed: 25922504
Psychiatry Res. 2009 May 15;172(2):117-20
pubmed: 19324534
Ann Neurol. 2012 Apr;71(4):552-9
pubmed: 22522444
Neurology. 2010 May 11;74(19):1502-10
pubmed: 20458066
Ann Neurol. 2012 Feb;71(2):199-205
pubmed: 22367992
Stroke. 2014 May;45(5):1292-8
pubmed: 24692481
Stroke. 2013 Mar;44(3):642-6
pubmed: 23391853
Eur Neurol. 2010;64(5):253-7
pubmed: 20881403
Cerebrovasc Dis. 2002;13 Suppl 2:31-6
pubmed: 11901240
J Neuropsychiatry Clin Neurosci. 2004 Winter;16(1):83-92
pubmed: 14990763
Stroke. 2010 Jan;41(1):34-40
pubmed: 19926840

Auteurs

Mahesh Kate (M)

Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Canada.

Laura Gioia (L)

Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Canada.

Thomas Jeerakathil (T)

Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Canada.

Michael D Hill (MD)

University of Calgary, Calgary, Canada.

Bronwen Gould (B)

Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Canada.

Rebecca McCourt (R)

Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Canada.

Dar Dowlatshahi (D)

University of Ottawa, Ottawa, Canada.

Shelagh Coutts (S)

University of Calgary, Calgary, Canada.

Jayme Kosior (J)

Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Canada.

Andrew Demchuk (A)

University of Calgary, Calgary, Canada.

Brian Buck (B)

Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Canada.

Kenneth Butcher (K)

Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Canada.
Prince of Wales Clinical School, University of New South Wales, Sydney, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH